Abstract
Treatment of metastatic melanoma remains a challenge. Two FDA-approved biological response modifiers -- interferon alfa (IFN) and interleukin 2 (IL2) -- were recently studied in phase III trials in Europe. The results did not surprise many but certainly disappointed all. Eggermont and colleagues, on behalf of the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group, randomized 1388 patients with resected stage III or thick (≥4.0 mm) melanomas to observation or to 13 or 25 months of intermediate-dose IFN (10 million units [MU], 5 days per week for 4 weeks, followed by …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
